Acyclovir: Nursing Drug Guide, Renal Dosing & NCLEX Review
Healthcare medication guide: hydration, renal dose adjustment, IV infusion rate limits, and neurotoxicity prevention when acyclovir accumulates from dehydration, missed renal dosing, bolus IV, or nephrotoxic co-therapy.
Acyclovir can cause renal failure (sometimes death) and CNS effects (agitation, confusion, tremor, seizure, coma)—especially with IV therapy, renal impairment, dehydration, advanced age, or nephrotoxic co-therapy. The highest-stakes nursing failures are inadequate hydration, missed renal dose adjustment, bolus or rapid IV push, and infusion concentrations above approximately 7 mg/mL. IV acyclovir must infuse over at least 1 hour. Verify creatinine clearance before every course, adjust oral (Table 3) and IV (Table 6) dosing, monitor intake/output and BMP trends, and hold plus escalate when creatinine rises or neuro symptoms appear.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every IV dose, confirm adequate hydration, current creatinine clearance with pharmacy-adjusted dosing, and a programmed infusion of at least 1 hour at ≤7 mg/mL—never bolus. Rising creatinine or new confusion on acyclovir means hold the dose and escalate for renal interval adjustment before the next infusion.
Most common brand names
Acyclovir is available as generic tablets/capsules/suspension and as IV lyophilized powder. Verify whether the order specifies oral or IV route—products are not interchangeable.
Common brand names include Zovirax (oral tablets, capsules, suspension, and IV). The oral prodrug valacyclovir (Valtrex) is converted to acyclovir in vivo; patients with hypersensitivity to either drug must not receive acyclovir per labeling.
Why we give it — Indications
Acyclovir treats herpesvirus infections. Nurses most often administer it for shingles (herpes zoster), genital herpes, cold sores (HSV), and varicella (chickenpox), with IV therapy reserved for severe or immunocompromised disease.
| Use | Detail |
|---|---|
| Herpes zoster (shingles) | Oral acyclovir is indicated for acute treatment of herpes zoster. Therapy is most effective when started within 48 hours of rash onset per labeling. |
| Genital herpes | Indicated for initial episodes, intermittent treatment of recurrences, and chronic suppressive therapy. Acyclovir is not a cure; it reduces episode duration and frequency. |
| Chickenpox (varicella) | Indicated for treatment of chickenpox in adults, adolescents, and children. Controlled studies initiated treatment within 24 hours of rash onset. |
| IV — immunocompromised HSV | IV acyclovir treats initial and recurrent mucosal/cutaneous HSV in immunocompromised patients. |
| IV — severe genital herpes, encephalitis, neonatal HSV, immunocompromised zoster | IV labeling covers severe initial genital herpes, HSV encephalitis, neonatal HSV, and varicella-zoster in immunocompromised patients per approved regimens. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Acyclovir is a synthetic purine nucleoside analogue active against HSV-1, HSV-2, and VZV. Selectivity depends on viral thymidine kinase (TK), which converts acyclovir to monophosphate; cellular enzymes form the triphosphate, which inhibits viral DNA polymerase, incorporates into viral DNA, and terminates the chain. Because acyclovir is renally cleared and can precipitate in tubules at high concentrations, nursing care must protect renal perfusion and infusion rate—not just viral coverage.
Dosing overview
Always verify the prescriber order against current prescribing information, indication, weight, and renal function. Adjust oral doses using Table 3 and IV doses using Table 6 when creatinine clearance is reduced.
Oral renal adjustment (Table 3)
| Normal regimen | CrCl (mL/min/1.73 m²) | Adjusted dose | Interval |
|---|---|---|---|
| 200 mg q4h ×5 daily | >10 | 200 mg | q4h, 5× daily |
| 200 mg q4h ×5 daily | 0–10 | 200 mg | q12h |
| 400 mg q12h | >10 | 400 mg | q12h |
| 400 mg q12h | 0–10 | 200 mg | q12h |
| 800 mg q4h ×5 daily | >25 | 800 mg | q4h, 5× daily |
| 800 mg q4h ×5 daily | 10–25 | 800 mg | q8h |
| 800 mg q4h ×5 daily | 0–10 | 800 mg | q12h |
On a small screen, swipe or scroll sideways to see the full table.
IV renal adjustment (Table 6)
| CrCl (mL/min/1.73 m²) | Percent of recommended dose | Dosing interval (hours) |
|---|---|---|
| >50 | 100% | 8 |
| >25 to 50 | 100% | 12 |
| >10 to 25 | 100% | 24 |
| ≤10 | 50% | 24 |
On a small screen, swipe or scroll sideways to see the full table.
Hemodialysis: Mean acyclovir half-life during dialysis is approximately 5 hours with ~60% decrease in plasma concentration over a 6-hour session—administer a supplemental dose after each dialysis per labeling.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses; contact pharmacy for the next scheduled dose if a dose is missed, especially when renal intervals are extended.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Oral half-life | 2.5–3.3 hours (labeling Table 1) | Renal impairment prolongs half-life—adjust interval, do not assume standard q4h oral schedule |
| Oral bioavailability | 10–20%; decreases with higher doses | Probenecid and renal dysfunction raise levels—monitor toxicity cues |
| IV peak (steady state) | ~9.8 mcg/mL at 5 mg/kg q8h; ~22.9 mcg/mL at 10 mg/kg q8h | Higher mg/kg regimens (zoster, encephalitis) carry greater renal and CNS risk if hydration or renal adjustment is missed |
| Elimination | Renally excreted unchanged (major route) | Rising creatinine or oliguria requires hold, hydration assessment, and dose/interval change |
| Food effect | No effect on oral absorption | May give oral acyclovir with or without food |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review BMP/creatinine clearance, urine output, hydration status, and concurrent nephrotoxic drugs (aminoglycosides, NSAIDs, contrast, other nephrotoxins per clinical context)
- Confirm allergy history to acyclovir and valacyclovir; verify oral vs IV route and that IV order specifies infusion over ≥1 hour—not IV push
- For IV: confirm final concentration ≤7 mg/mL, weight-based mg/kg dose, and pharmacy renal adjustment applied to Table 6
Contraindications
- Hypersensitivity to acyclovir or valacyclovir
- Oral capsules/tablets are for oral ingestion only; IV formulation is for intravenous infusion only (not IM, SC, topical, oral, or ocular per IV labeling)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Probenecid | Increases acyclovir half-life and AUC; reduces renal clearance | Flag to pharmacy; monitor creatinine and neuro symptoms more closely |
| Nephrotoxic co-therapy + dehydration | Increased risk of renal dysfunction and crystal precipitation with acyclovir | Ensure hydration, monitor I&O and BMP; hold and escalate if creatinine rises |
| Renal impairment | Prolonged half-life and toxicity risk (renal and CNS) | Apply Table 3 (oral) or Table 6 (IV); recheck eGFR/CrCl during long courses |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: Tablets, capsules, or suspension per order. May administer with or without food. Maintain adequate hydration.
IV: Reconstitute vial per labeling (50 mg/mL), then dilute for infusion. Infuse over at least 1 hour at a constant rate using IV infusion pump setup after appropriate IV insertion. Do not administer bolus or rapid IV push. Recommended infusion concentration is approximately 7 mg/mL or lower. Inspect for particulate matter; use diluted dose within 24 hours.
- Program pump for 1-hour minimum infusion; rapid infusion (<10 minutes) has been associated with elevated creatinine in labeling
- Ensure adequate IV fluids and oral intake when tolerated—hydration reduces tubular crystal risk
- Document actual infusion start/stop times, volume, and concentration on the MAR
Labeling warns that precipitation in renal tubules occurs when acyclovir solubility (2.5 mg/mL in intratubular fluid) is exceeded—often with bolus injection, high concentration, dehydration, or missed renal adjustment. Extravasation can cause severe local inflammation and tissue necrosis.
Expected therapeutic response
- Shortened time to lesion scabbing/healing and reduced new lesion formation in zoster and HSV per trial labeling
- Decreased duration of viral shedding and pain in treated zoster when started early
- Improved chickenpox symptoms (fewer lesions, shorter fever duration) when started within 24 hours of rash
- Stable or improving renal function and mental status while on therapy—any worsening requires reassessment before the next dose
Red flags — Stop and act
Renal failure and neurotoxicity can progress quickly when acyclovir accumulates. Hold the dose and escalate immediately.
- Rising creatinine, elevated BUN, oliguria, or renal pain suggesting acute kidney injury
- Agitation, confusion, tremor, hallucinations, seizure, lethargy, or coma—especially after IV therapy or in elderly/renally impaired patients
- Signs of TTP/HUS in immunocompromised patients (labeling warning—can be fatal)
- Anaphylaxis, angioedema, or serious skin reaction (rash, Stevens-Johnson syndrome, toxic epidermal necrolysis)
- IV site extravasation, phlebitis, or inflammation—stop infusion and follow extravasation protocol
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, vomiting, diarrhea, malaise | Common in oral trials (indication-dependent) | Supportive care; differentiate from neurotoxicity if confusion or tremor co-occur |
| Phlebitis / injection-site inflammation | ~9% IV; higher with rapid infusion | Verify 1-hour infusion and concentration ≤7 mg/mL; assess IV site each hour |
| Elevated creatinine / BUN | 5–10% IV trials; more with rapid infusion | Hold dose, hydrate, notify prescriber/pharmacy for renal adjustment; trend BMP |
| CNS effects (agitation, confusion, seizure, coma) | Post-marketing; marked in elderly/renal impairment | Stop acyclovir, monitor neuro status, notify prescriber urgently |
| Renal failure | Serious; can be fatal (Warnings) | Hold drug, nephrology/prescriber escalation, consider hemodialysis if anuric per overdose guidance |
| TTP/HUS | Reported in immunocompromised patients (fatal cases) | Stop acyclovir, urgent hematology/MD evaluation |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdoses involving up to 20 g oral or inappropriate IV bolus/high doses have been reported. Crystal precipitation in renal tubules may occur when solubility is exceeded.
Reported overdose effects
- Agitation, coma, seizures, lethargy
- Elevated BUN and creatinine with acute renal failure—especially after bolus or inadequate hydration monitoring
Management
Supportive care per clinical status. In acute renal failure with anuria, the patient may benefit from hemodialysis until renal function is restored per labeling. No specific antidote is listed in the reviewed prescribing information.
Look-alike / sound-alike and error prevention
- Acyclovir vs valacyclovir—prodrug vs active drug; cross-hypersensitivity contraindicates both
- Acyclovir vs aciclovir—same drug, international spelling; verify MAR entry
- Oral vs IV acyclovir—never substitute routes; IV requires dilution and 1-hour infusion
- IV push vs IV infusion—bolus/rapid injection is contraindicated and a common high-risk error
- mg/kg vs mg flat dose—IV orders are weight-based; independent double-check with pharmacy
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Hydration | Encourage oral fluids when safe; maintain IV fluids per order—adequate hydration is listed in precautions for oral and IV products |
| IV concentration | Target ≤7 mg/mL; higher concentrations (e.g., 10 mg/mL) increase phlebitis/extravasation risk per IV labeling |
| CrCl timing | Check BMP before starting and during long IV courses; adjust before the next dose if creatinine rises |
| Dialysis | Schedule supplemental dose after hemodialysis per labeling |
| Commonly missed | Continuing standard q8h IV after creatinine rise; rapid piggyback; oral schedule not changed when CrCl <25 |
| Ask pharmacy when | Renal adjustment needed, probenecid interaction, obese ideal body weight IV dosing, or reconstitution/dilution questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal impairment | Dose adjustment required (Table 3 oral, Table 6 IV). Renal failure, sometimes fatal, reported with acyclovir therapy. |
| Immunocompromised patients | Higher IV exposure; TTP/HUS reported. Monitor renal function and hematologic status closely. |
| Older adults | Higher plasma levels, greater renal and CNS adverse events; nausea, vomiting, dizziness reported more frequently in geriatric zoster trials. Reduce dose when CrCl impaired. |
| Neonates / infants | IV neonatal regimens by post-menstrual age per IV labeling; use caution when renal function is affected beyond prematurity. |
| Pregnancy | Pregnancy category B per labeling; no adequate controlled studies—use only if potential benefit justifies potential risk. |
| Lactation | Acyclovir excreted in breast milk (0.6–4.1× plasma levels reported). LactMed: infant exposure ~1% of typical infant dose; considered treatment of choice for herpes during breastfeeding when indicated. Use caution and only when indicated per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Creatinine, BUN, and urine output—especially during IV therapy and when nephrotoxic drugs co-exist
- Mental status, tremor, agitation, or seizure activity (CNS toxicity risk with IV and renal impairment)
- IV site for phlebitis, extravasation, and infusion rate compliance (≥1 hour)
- Lesion healing, pain, and fever trend for the treated herpesvirus infection
Document
- Dose, route, weight, infusion start/stop, concentration, and verified renal adjustment on MAR
- Intake/output and hydration teaching provided
- Creatinine clearance source and date when renal-modified schedule used
Patient teaching
- Drink adequate fluids unless fluid-restricted—hydration reduces kidney injury risk with acyclovir
- Complete the full prescribed course even if lesions improve; do not share medication
- For genital herpes: acyclovir is not a cure; avoid sexual contact when lesions or symptoms are present to reduce transmission
- Report decreased urination, flank pain, confusion, tremor, severe rash, or breathing difficulty immediately
- Breastfeeding patients: discuss risks and benefits with the prescriber; LactMed supports use when herpes treatment is indicated
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to acyclovir or valacyclovir
- Rising creatinine, oliguria, or acute kidney injury while on acyclovir
- IV order written as bolus, IV push, or infusion <1 hour, or concentration >7 mg/mL without pharmacy approval
- New neurotoxicity symptoms (confusion, agitation, tremor, seizure, lethargy)
- Order lacks required renal adjustment when CrCl is ≤50 mL/min/1.73 m² (IV) or meets Table 3 thresholds (oral)
- Significant dehydration or inability to maintain hydration until plan clarified
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
IV acyclovir is often ordered on busy med-surg or oncology units where dehydration, aminoglycosides, and contrast exposure overlap—exactly the conditions labeling links to renal crystal precipitation. Build renal safety into the medication pass, not only infection treatment.
1. Check-before-you-give protocol
- Right patient, dose, route, time—and right creatinine clearance adjustment
- IV: verify mg/kg, dilution concentration ≤7 mg/mL, and pump duration ≥1 hour
- Confirm hydration status and nephrotoxic drug overlap on MAR
- Compare today’s creatinine to baseline before starting or continuing IV therapy
2. High-alert and safety badge
High renal-risk IV medication — infusion rate and hydration criticalIV labeling requires minimum 1-hour infusion, prohibits bolus, and links rapid administration to elevated creatinine. Treat programming and hydration with the same rigor as institutional high-alert medications.
3. Clinical workflow: hold and question rules
- If creatinine rises ≥0.3–0.5 mg/dL from baseline or urine output drops, hold the next dose pending pharmacy renal interval adjustment
- If the patient receives probenecid or new nephrotoxic therapy, notify pharmacy before the next acyclovir dose
- Any confusion or tremor on IV acyclovir triggers neuro assessment and prescriber notification—do not restart until cleared
4. Critical teach-back questions
- “Why is it important to drink fluids while taking acyclovir?” (Patient should link fluids to protecting the kidneys while the drug is cleared renally.)
- “What symptoms should you report right away?” (Patient should name decreased urination, confusion, severe rash, or trouble breathing.)
5. Care coordination
Pharmacist: Renal dose adjustment (Table 3/6), IV dilution concentration, probenecid interaction, dialysis supplemental dosing
Prescriber / nephrology: Rising creatinine, oliguria, persistent neuro symptoms, or need to change route when renal function declines
🧠 Quick mental checklist
- What is this patient’s creatinine clearance and most recent creatinine trend?
- Is the patient adequately hydrated—and are nephrotoxic drugs on the MAR?
- For IV: is this programmed for ≥1 hour at ≤7 mg/mL—not bolus?
- Has pharmacy applied Table 6 (IV) or Table 3 (oral) if renal function is impaired?
- Any new confusion, tremor, seizure, or decreased urine output since the last dose?
Acyclovir NCLEX practice questions
Practice NCLEX-style clinical judgment practice for acyclovir renal and IV safety using a tabbed inpatient case (MAR, labs, intake/output, nursing notes), then priority action, cue recognition (SATA), creatinine trend interpretation, documentation cloze, ordered response, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Acyclovir IV 5 mg/kg (350 mg for 70 kg) q8h — given 0600, 1400; next due 2200
- Vancomycin IV per pharmacy protocol (trough-ordered) — 0900 dose given
- 0.9% NaCl maintenance IV 75 mL/h — running; 500 mL bolus given 1600 for poor intake
- Pump check: 1400 dose documented as completed over 30 minutes (misprogrammed)
- Admission: creatinine 1.0 mg/dL; BUN 18 mg/dL; eGFR 78 mL/min/1.73 m²; CrCl estimated 78 mL/min
- Day 2: creatinine 1.4 mg/dL; BUN 24 mg/dL; eGFR 52 mL/min/1.73 m²
- Today (day 3, 1800): creatinine 1.8 mg/dL; BUN 28 mg/dL; eGFR 38 mL/min/1.73 m²
- Repeat BMP ordered per pharmacy; renal dose adjustment for acyclovir pending
- 0800–1200: intake 420 mL IV + 120 mL oral; output 180 mL (≈45 mL/h)
- 1200–1600: intake 310 mL IV; output 60 mL (≈15 mL/h) — oliguria noted
- 1600–1800 (post bolus): output 50 mL in 2 h (≈25 mL/h)
- Running 24 h balance: intake 1350 mL; output 290 mL
- 62-year-old with chemotherapy-induced immunosuppression; mucosal HSV; day 3 of IV acyclovir
- Poor oral intake × 2 days; patient reports dry mouth; refuses most meals
- 1800: alert and oriented; reports mild hand tremor; denies chest pain or flank pain
- Infusion audit: prior acyclovir dose ran 30 min instead of ≥1 h; pharmacy notified to review MAR
Answer key & rationale
Frequently asked questions
Why must IV acyclovir be infused over at least 1 hour?
IV acyclovir labeling states infusions must be given over at least 1 hour to reduce renal tubular damage. Rapid or bolus injection can exceed acyclovir solubility in renal tubules, causing crystal precipitation, acute renal failure, and elevated creatinine.
How should nurses adjust acyclovir when creatinine clearance falls?
Oral acyclovir uses Table 3 dose and interval adjustments by creatinine clearance. IV acyclovir uses Table 6 percent-of-dose and extended dosing intervals for CrCl ≤50 mL/min/1.73 m², with 50% dose and 24-hour interval when CrCl ≤10. Hemodialysis patients need a supplemental dose after each dialysis per labeling.
When should a nurse hold acyclovir and call the prescriber or pharmacist?
Hold for known hypersensitivity to acyclovir or valacyclovir, rising creatinine or oliguria suggesting nephrotoxicity, IV orders for bolus or rapid push, concentration above approximately 7 mg/mL, inadequate hydration, new neurotoxicity symptoms (confusion, tremor, seizure), or orders that omit required renal adjustment.
Is acyclovir safe during pregnancy and breastfeeding?
Prescribing information lists pregnancy category B with no adequate controlled studies in humans; use only if potential benefit justifies risk. LactMed states milk levels represent about 1% of a typical infant dose and acyclovir is considered a treatment of choice for herpes during breastfeeding when indicated.
What are signs of acyclovir overdose or toxicity?
Overdose labeling reports agitation, coma, seizures, and lethargy. Crystal precipitation in renal tubules can cause elevated BUN and creatinine with renal failure. Management is supportive; hemodialysis may benefit patients with acute renal failure and anuria. No specific antidote is listed.
Does probenecid interact with acyclovir?
Yes. Labeling states coadministration of probenecid increases the mean acyclovir half-life and area under the curve while reducing urinary excretion and renal clearance, which can raise acyclovir levels and renal risk—coordinate with pharmacy when both drugs are ordered.
References
- U.S. National Library of Medicine. Acyclovir tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e203fa9-ee97-1e08-8d6a-fb57cfa13e19
- U.S. National Library of Medicine. Acyclovir for injection, USP — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca54c058-808e-4ad2-a33e-07796a4b27d4
- Drugs and Lactation Database (LactMed). Acyclovir. Bethesda (MD): National Institute of Child Health and Human Development; updated February 15, 2026.https://www.ncbi.nlm.nih.gov/books/NBK501195/
- U.S. National Library of Medicine. Acyclovir — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a681045.html
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.https://www.accessdata.fda.gov/scripts/medwatch/
- National Library of Medicine. Drugs and Lactation Database (LactMed) — About and peer review. NCBI Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK501922/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.